戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              CPMV also exhibited clear treatment efficacy and systemi
2                                              CPMV and eCPMV could each be developed as novel adjuvant
3                                              CPMV nanoparticles are stable, nontoxic, modifiable with
4                                              CPMV or QB VLPs could be stockpiled, and epitopes exchan
5                                              CPMV-eVLP mimic the morphology of wild-type (WT) CPMV bu
6 ne the immunotherapeutic differences between CPMV and eCPMV, which is essential for the further devel
7 onstrated, the specific interactions between CPMV and mammalian cells need to be characterized furthe
8  cancer cells (cervical, breast, and colon): CPMV nanoparticles enter cells via the surface marker vi
9 nes and immune cells, but the RNA-containing CPMV particles were uniquely able to boost populations o
10 taining RNA-2, and of naturally-formed empty CPMV capsids.
11 like nanoparticles (VLPs) based on the empty CPMV (eCPMV) virion.
12 ediated tumor angiogenesis using fluorescent CPMV provides a means to identify arterial and venous ve
13 eading to the development of dual-functional CPMV carrier systems.
14                                 Furthermore, CPMV-CD46 protected mice from mortality induced by an in
15 on of CPMV-BP is important to understand how CPMV is trafficked through the mammalian system and may
16  the Cowpea Mosaic Virus hypertranslational "CPMV-HT" expression system, which provides high yields o
17          As well as an intrinsic interest in CPMV as a plant pathogen, CPMV is of major interest in b
18                                Cargo-infused CPMV nanoparticles remain chemically active, and surface
19                                      Inhaled CPMV nanoparticles were rapidly taken up by and activate
20 lian cells nevertheless bind and internalize CPMV in significant amounts.
21 hich allowed subgrouping of comoviruses into CPMV-like and BPMV-like viruses.
22  ovalbumin (OVA) as a model antigen, OVA-Lip-CPMV vaccination protects mice from lung metastasis post
23 -Luc tumor model in female mice, the TCL-Lip-CPMV conjugate vaccine protects mice from tumor challeng
24 cy against a poorly immunogenic tumour, make CPMV an attractive and novel immunotherapy against metas
25              Although the bioavailability of CPMV in the mouse has been demonstrated, the specific in
26  the ability to produce assembled capsids of CPMV in the absence of replication to examine the putati
27                  Further characterization of CPMV-BP is important to understand how CPMV is trafficke
28 The CD46 peptide presented in the context of CPMV is also up to 100-fold more effective than the solu
29 r results will facilitate the development of CPMV and eCPMV as immunotherapeutic vaccine platforms wi
30 ll assist further work in the development of CPMV as a biotechnological tool.
31 revious reports described the engineering of CPMV through genetic or chemical modification, we report
32 bly detecting the virus in crude extracts of CPMV-infected leaves and can therefore form the basis fo
33 oreover, we demonstrate that this feature of CPMV can be used to specifically encapsidate custom RNA
34 vide a useful means for functionalization of CPMV toward its application as drug and/or contrast agen
35 al to understand the in vivo interactions of CPMV within the mammalian system.
36 t although the host range for replication of CPMV is confined to plants, mammalian cells nevertheless
37 ory CD46 peptide expressed on the surface of CPMV retains virus-binding activity and is capable of in
38 rinsic interest in CPMV as a plant pathogen, CPMV is of major interest in biotechnology applications
39 ion of 130-155 fluorescent dye molecules per CPMV using DAPI (4',6-diamidino-2-phenylindole dihydroch
40 bitors showed that the CPMV binding protein (CPMV-BP) is not glycosylated.
41                                         Such CPMV-peptide chimeras can be easily and inexpensively pr
42                    In physicochemical terms, CPMV and eCPMV were very similar, and both significantly
43                                 We show that CPMV nanoparticles can be used to visualize the vasculat
44                                          The CPMV-CD46 chimera efficiently inhibited MV infection of
45        Thanks to the bipartite nature of the CPMV genome, which allows the manipulation of RNA-1 with
46             A possible 47-kDa isoform of the CPMV-BP was also detected in the organelle and nuclear s
47 and glycosylation inhibitors showed that the CPMV binding protein (CPMV-BP) is not glycosylated.
48                      This study utilized the CPMV chimera platform to create an antiviral against mea
49 ed through interaction of the cargo with the CPMV's encapsidated RNA molecules.
50  reagent selected for its ability to bind to CPMV-eVLP and have shown that the selected Affimer also
51 ctron microscopy (cryo-EM) maps of wild type CPMV containing RNA-2, and of naturally-formed empty CPM
52 tion of HeLa cells in vitro, while wild-type CPMV did not.
53 properties of wild-type cowpea mosaic virus (CPMV) (RNA containing) and eCPMV (RNA-free VLPs) produce
54  two other comoviruses, Cowpea mosaic virus (CPMV) and Bean pod mottle virus (BPMV).
55        The bioavailable cowpea mosaic virus (CPMV) can be fluorescently labeled to high densities wit
56 and a model plant virus Cowpea Mosaic virus (CPMV) empty virus like particles (eVLPs).
57         The plant virus cowpea mosaic virus (CPMV) has recently been developed as a biomolecular plat
58                         Cowpea mosaic virus (CPMV) is a picorna-like plant virus.
59                         Cowpea mosaic virus (CPMV) is a plant virus that has been developed for multi
60 the peptide epitopes to cowpea mosaic virus (CPMV) nanoparticles and virus-like particles (VLPs) deri
61 like nanoparticles from cowpea mosaic virus (CPMV) reduces established B16F10 lung melanoma and simul
62 ch are then attached to cowpea mosaic virus (CPMV), a plant virus as a potent adjuvant.
63                         Cowpea mosaic virus (CPMV), a plant virus that is a member of the picornaviru
64 g member of this order, cowpea mosaic virus (CPMV), to decouple the two processes.
65 0), vaccinia (MVA), and cowpea mosaic virus (CPMV), were compared by AC capacitance scanning probe mi
66 specifically 30nm-sized cowpea mosaic virus (CPMV).
67 ottle virus (CCMV), and cowpea mosaic virus (CPMV).
68 have produced a 3.4 angstrom structure of WT CPMV bound to the Affimer using cryo-electron microscopy
69 lected Affimer also specifically binds to WT CPMV.
70 -eVLP mimic the morphology of wild-type (WT) CPMV but lack any infectious genomic material and so do